Literature DB >> 32877761

Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway.

Sabah Akhtar1, Shireen Hourani1, Lubna Therachiyil2, Abdullah Al-Dhfyan3, Abdelali Agouni1, Asad Zeidan4, Shahab Uddin5, Hesham M Korashy6.   

Abstract

Compelling evidence has demonstrated that tumor bulk comprises distinctive subset of cells generally referred as cancer stem cells (CSCs) that have been proposed as a strong sustainer and promoter of tumorigenesis and therapeutic resistance. These distinguished properties of CSCs have raised interest in understanding the molecular mechanisms that govern the maintenance of these cells. Numerous experimental and epidemiological studies have demonstrated that exposure to environmental toxins such as the polycyclic aromatic hydrocarbons (PAHs) is strongly involved in cancer initiation and progression. The PAH-induced carcinogenesis is shown to be mediated through the activation of a cytosolic receptor, aryl hydrocarbon receptor (AhR)/Cytochrome P4501A pathway, suggesting a possible direct link between AhR and CSCs. Several recent studies have investigated the role of AhR in CSCs self-renewal and maintenance, however the molecular mechanisms and particularly the epigenetic regulations of CSCs by the AhR/CYP1A pathway have not been reviewed before. In this review, we first summarize the crosstalk between AhR and cancer genetics, with a particular emphasis on the mechanisms relevant to CSCs such as Wnt/β-catenin, Notch, NF-κB, and PTEN-PI3K/Akt signaling pathways. The second part of this review discusses the recent advances and studies highlighting the epigenetic mechanisms mediated by the AhR/CYP1A pathway that control CSC gene expression, self-renewal, and chemoresistance in various human cancers. Furthermore, the review also sheds light on the importance of targeting the epigenetic pathways as a novel therapeutic approach against CSCs.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Aryl hydrocarbon receptor; CYP1A1; CYP1B1; Cancer stem cells; Chemoresistance; DNA methylation; Epigenesis; Histone modification; MicroRNAs

Mesh:

Substances:

Year:  2020        PMID: 32877761     DOI: 10.1016/j.semcancer.2020.08.014

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  3 in total

1.  Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis.

Authors:  Kuo-Min Su; Hong-Wei Gao; Chia-Ming Chang; Kai-Hsi Lu; Mu-Hsien Yu; Yi-Hsin Lin; Li-Chun Liu; Chia-Ching Chang; Yao-Feng Li; Cheng-Chang Chang
Journal:  Biomedicines       Date:  2021-07-22

2.  BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells.

Authors:  Ali Alhoshani; Fahad O Alatawi; Fawaz E Al-Anazi; Ibraheem M Attafi; Asad Zeidan; Abdelali Agouni; Heba M El Gamal; Licia S Shamoon; Sarah Khalaf; Hesham M Korashy
Journal:  Onco Targets Ther       Date:  2020-12-31       Impact factor: 4.147

3.  The MicroRNA-106a/20b Strongly Enhances the Antitumour Immune Responses of Dendritic Cells Pulsed with Glioma Stem Cells by Targeting STAT3.

Authors:  Hui Zhou; Chengmei Sun; Cong Li; Shiting Hua; Feng Li; Ruichun Li; Dongpeng Cai; Yuxi Zou; Yingqian Cai; Xiaodan Jiang
Journal:  J Immunol Res       Date:  2022-09-15       Impact factor: 4.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.